ArticleFrontiers in bioengineering and biotechnology2026
Insights into the biological effects of molybdenum in an insect model (
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Molybdenum (Mo) is a potential biodegradable stent material that has excellent mechanical and degradation properties. Recent studies suggest that chronic exposure to Mo is associated with renal concerns. Methods: Fifth instar Results: Mo was non-toxic at all concentrations. Colorimetric assays of MDA and SOD in hemolymph and in the MT were comparable across the treatment groups. Morphological changes were observed in the cryptonephridial complex (CNC) of the MT tubules with 10 mM Mo treatment alluding to dilation of the MT. Two photon FLIM indicated the likely presence of the metabolic species (NAD(P)H) (blue channel) with an increase in mean lifetime (Tm) and an increase of protein binding of NAD(P)H at 200 mM of Mo treatment favoring oxidative phosphorylation. Discussion: In summary, we confirmed non-toxicity of Mo in the invertebrate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.